Navigation Links
Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients
Date:11/1/2008

dose has occurred in patients on PEGINTRON therapy. Aggressive behavior sometimes directed towards others has occurred in patients with and without a previous psychiatric disorder during PEGINTRON and/or INTRON A treatment and follow-up. If patients develop psychiatric problems, including clinical depression, it is recommended that patients be carefully monitored during treatment and in the 6-month follow-up period. If psychiatric symptoms persist or worsen, or suicidal ideation or aggressive behavior towards others is identified, it is recommended that treatment with PEGINTRON and/or INTRON A be discontinued, and the patient be carefully followed with psychiatric intervention, as appropriate. Cases of encephalopathy have been observed in some patients, usually elderly, treated with higher doses of PEGINTRON and/or INTRON A. Ischemic and hemorrhagic cerebrovascular events have been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. Dental and periodontal disorders have been reported in patients receiving PEGINTRON or INTRON A in combination with REBETOL therapy.

Please see important full U.S. prescribing information and the Medication Guide for PEGINTRON at http://www.schering-plough.com.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
2. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
3. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
4. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
5. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
6. Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
9. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
10. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- Perrigo Company plc ("Perrigo") (NYSE: PRGO ; ... MYL ) shareholder vote regarding its planned unsolicited ... Mylan,s offer to Perrigo shareholders have always been, and ... reflection of the value available to Perrigo shareholders, and ... has allowed its shareholders to consider," said Joseph ...
(Date:8/28/2015)... , Joint research by Prof. Kim ... , Published in ,Stem Cells Translational Medicine, (IF ... multiple IV administration of Adipose-derived MSC , Increase ... , Commercialization within 5 years expected ... adult mesenchymal stem cells (MSCs) may extend healthy life ...
(Date:8/28/2015)... , August 28, 2015 The ... reach USD 49.12 billion by 2020, growing at a ... a new report by Grand View Research, Inc. Monitoring ... of 49.7% from 2014 to 2020.      ... population along with rising incidences of chronic diseases such ...
Breaking Medicine Technology:Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5
... , SANTA ROSA, Calif. , Feb. 16 ... Osseoplasty™ procedures in Europe . The procedures were performed in ... Incorporado, SL, the largest independent medical device distributor in Europe ... weeks in the United Kingdom , Germany and ...
... , , CRANBURY, N.J. , ... today announced financial results for the fourth quarter and full year ... product pipeline related to its key strategic priorities for 2010.  Additionally, ... achieve its key milestone of completing enrollment for its Phase 3 ...
Cached Medicine Technology:Osseon Launches in Europe 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 3Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 4Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 5Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 6Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 7Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 8Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 9Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 10Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 11
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... Device Library for documenting and diagramming network and data center assets and audio-video ... / Device Model, Cisco Nexus 5000 Series, HP ProLiant Gen9, EMC VNX Series ...
(Date:8/28/2015)... ... August 28, 2015 , ... Medical Solutions, one of the nation’s ... to Work in Healthcare by Modern Healthcare and will be honored at an ... its eighth year, the Best Places to Work in Healthcare program recognizes outstanding employers ...
(Date:8/28/2015)... ... August 28, 2015 , ... CARF International announced that West ... day treatment and intensive family based services. , By pursuing and achieving accreditation, ... pursuit of excellence. As a nonprofit charity for more than 50 years, West ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... loyalty at a low cost. Personalized with practice contact information and logos, Calendars ... Dental offices can also incorporate Calendars into seasonal mailings, thank you and welcome ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... Northridge ... on Zoom teeth whitening. For just $199, patients can currently receive a one hour ... in-office teeth whitening procedures, but it includes a number of unique features that can ...
Breaking Medicine News(10 mins):Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2
... Boston, MA -- Eating disorders among adolescent girls and ... and lead to dangerous weight-control behaviors, such as self-induced ... weight. The middle school age is a high risk ... dangerous weight-control behaviors that affect millions of Americans. Researchers ...
... 8.7 percent of U.S. children age 8 to ... fewer than half receive treatment, according to a ... Pediatrics & Adolescent Medicine, one of the JAMA/Archives ... of attention-deficit/hyperactivity disorder (ADHD) is on the rise, ...
... age 12 to 19 years who received family-based treatment ... than those who received supportive psychotherapy, which explores the ... in the September issue of Archives of General Psychiatry, ... is a disabling eating disorder with a prevalence of ...
... need, researchers say , , MONDAY, Sept. 3 (HealthDay News) ... disorder (ADHD), but only 32 percent of them are ... conclusion of a landmark new study, the first of ... standard" of diagnostic criteria -- the Diagnostic and Statistical ...
... SDAX as Per September 6, 2007 ... Outside the Normal Schedule, Decision on Possible ... Germany, September 3 Gerresheimer AG has,been listed in the Prime Standard ... largest IPOs of the year, with a total,issue volume of more than ...
... Belgium, September 3 KFH has announced that ... ISO 13485 and ISO,9001:2000 quality management systems with ... Dr Sally Sennitt, MD, says: "We are delighted,to ... systems,through working with BSI. It is a major ...
Cached Medicine News:Health News:School-based overweight prevention program may cut risk of eating disorders among girls 2Health News:Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD 2Health News:Family-based treatment more effective than supportive psychotherapy in treating bulimia 2Health News:9% of U.S. Kids Have ADHD 2Health News:9% of U.S. Kids Have ADHD 3
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
... The Featured Products are ... Mediflex and are offered ... in regular or extra ... equipped with insulation, flush ...
Medicine Products: